Proton Beam Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PTHP)
Status
Conditions
Treatments
Details and patient eligibility
About
The standard treatment of advanced hepatocellular carcinoma (HCC) is sorafenib. Though the agent showed clear survival benefit in two randomized phase III trials, the benefit was modest and response rate was just a few percent. Therefore, other loco-regional modalities, like trans-arterial chemo-embolization (TACE), hepatic arterial infusion chemotherapy (HAIC), and radiotherapy (RT) were continuously tried, especially in locally advanced HCC including portal vein tumor thrombosis (PVTT).
With the advancement of conformal RT techniques, RT was actively applied in HCC, especially in PVTT combined HCC. Many researchers reported that there is a relationship between RT dose and tumor response rate. RT dose, however, is frequently limited because the complications (like radiation induced liver disease (RILD), radiation induced gastro-duodenal toxicity, etc.) are also closely related with higher exposed RT dose.
Proton beam has characteristic depth-dose distribution contrast to photon, the "Bragg peak". The advantage of this dose distribution could be more highlighted in HCC management, because of the weakness and maintenance importance of liver function itself in HCC patients. In fact, the superior results of proton beam therapy in HCC were constantly reported in several groups as prospectively as well as retrospectively.
In those background, the investigators planned the present study to evaluate the efficacy and safety of proton beam therapy in HCC patients combined with PVTT.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Hepatocellular carcinoma (HCC) patients
- pathologically proven
- HCC diagnosed based on American Association for the Study of Liver Diseases (AASLD) guideline
- Portal vein tumor thrombosis (main, first branch, segmental)
- Discussion in tumor board including gastroenterologist, radiologist, radiation oncologist
- 20 or more age
- Eastern Cooperative Oncology Group performance status 0 to 2 within 1 week before participate
- Adequate bone marrow function (absolute neutrophil count ≥ 1.0 x 109/l, platelet ≥ 30 x 109/l, hemoglobin ≥ 8 g/dl)
- Adequate liver/renal function within 1 week before participate
- Child-Pugh class A, B, or early C (score ≤ 10)
- Total bilirubin <3.0 mg/dL, Prothrombin time/International normalized ratio <1.7, Albumin≥2.8g/dL, Aspartate aminotransferase/alanine aminotransferase<6 times of upper normal limit
- Serum creatinine < 1,5 x upper normal limit, glomerular filtration rate > 50 ml/min Informed consent
- Women of childbearing potential and male participants must agree to practice adequate contraception while on study and for at least 6 months following the last dose of RT and for at least 28 days following the last dose of sorafenib (whichever is later).
Exclusion criteria
- Uncontrolled hepatic encephalopathy
- Previous history of upper abdominal radiotherapy
- Status of pregnancy or breast feeding
- Less than 12 weeks of expected survival
- Uncontrolled ascites
- Combined with disease known as radiosensitive disorder (connective tissue disorder, Ataxia-telangiectasia)
- Hard to maintain stable respiration less than 5 minutes related with respiratory disease
- Combined with uncontrolled severe acute disease other than liver
Trial design
Primary purpose
Allocation
Interventional model
Masking
53 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Hee Chul Park, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal